New Delhi, July 21 -- Lupin Limited's wholly owned US subsidiary, Lupin Inc., has licensed two oncology drug programmes to newly established American firm Kaveri Therapeutics Inc. for USD 1.6 million, the company said in a regulatory filing.

Lupin said Lupin Inc. has entered into a licensing agreement granting Kaveri Therapeutics an exclusive perpetual licence for two of its oncology programmes -- LNP7457 (PRMT5) and LNP8701 (SOS1) -- in exchange for an 82.2 per cent equity stake in the US-based company.

The transaction was completed on July 20, 2026, simultaneously with the execution of the licensing agreement. As part of the deal, Lupin Inc. received 332,000 common shares in Kaveri Therapeutics, valued at USD 1.6 million.

According t...